• Latest Posts

Why did Biotech Beat Pharma to Bring the First Gene Therapy to Market?

The Largest Deals, Fundraising and Exits of 2016 in European Biotech

Green Light for Genfit to Tackle another Liver Disease

Genfit’s Non-Invasive Diagnostic could unlock the NASH Market

Beyond NASH: Genfit jumps into another Critical Liver Condition

Genfit Has Enroled its First Patient in a NASH Phase III Trial

ADVERTISEMENT

10 Hot European Biotechs to watch in 2016

Interview with the CEO of Genfit – The Billion Euro Liver Biotech on its phase III NASH Drug

Boehringer kindles NASH treatments with Pharmaxis’ drug acquisition

ADVERTISEMENT